3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Other hematologic neoplasm
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Leukemia, Myeloid, Acute
2
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma
1
Recurrence
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Myelodysplastic Syndromes
1
Melanoma
1
Lung Neoplasms
1
Liver Neoplasms
1
Leukemia
1
Kidney Neoplasms
1
High-risk Leukemias
1
Head and Neck Neoplasms
1
Glioblastoma
1
Esophageal Neoplasms
1
Disease
1
Colorectal Neoplasms
1
Carcinoma, Bronchogenic
1
Breast Neoplasms
1
Interventions
Carboplatin
6
Pemetrexed
3
Paclitaxel
3
atezolizumab
2
Radiosurgery
2
Gemcitabine
2
Docetaxel
2
Cisplatin
2
pembrolizumab
1
durvalumab
1
cemiplimab
1
Vinorelbine
1
Tyrosine Kinase Inhibitors
1
Radiotherapy
1
Platinum Compounds
1
Nivolumab
1
Mediastinoscopy
1
Magnetic Resonance Spectroscopy
1
Interleukin-15
1
Fluticasone
1
Exercise Therapy
1
Etoposide
1
Dasatinib
1
Bronchoscopy
1
Blood Specimen Collection
1
Bevacizumab
1
Afatinib
1
Acetylcysteine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Carcinoma, Bronchogenic
×
Interleukin-15
×
Clear all
NCT07410676
2026-02-18
EBNK-ST-001
Essen Biotech
Phase 1/2
Recruiting
83 enrolled